Skip to main content
Premium Trial:

Request an Annual Quote

Waters Q2 Revenues up 31 Percent

NEW YORK – Waters reported on Tuesday that its second quarter revenues were up 31 percent year over year.

For the three months ended June 29, the company posted revenues of $681.6 million, up 31 percent from $520.0 million in Q2 2020, and above the average Wall Street estimate of $621.5 million. Organic revenues grew 27 percent, with foreign currency translation boosting revenues by 4 percent, the company said.

By end market, pharma sales were up 34 percent to $416.7 from $311.0 million; government and academic sales rose 10 percent to $62.4 million from $56.9 million; and industrial sales rose 33 percent to $202.6 million from $152.1 million.

Waters' recurring revenues, which include its services and consumables businesses, rose 22 percent during the quarter to $367.2 million from $300.2 million, while instrument sales were up 43 percent to $314.5 million from $219.8 million.

Waters CEO Udit Batra said in a statement accompanying release of the Q2 earnings that the results "were led by strong growth in our pharma and industrial end markets … with total sales increasing across every region."

Waters' Q2 net income was $167.3 million, or $2.69 per share, compared to $123.0 million, or $1.98 per share, a year ago. On a non-GAAP basis, the company reported EPS of $2.60, beating analysts' average estimate of $2.24.

Water's R&D spending in Q2 was up 44 percent to $44.9 million from $31.2 million a year ago, while SG&A costs rose 35 percent to $158.2 million from $117.4 million.

The company ended the quarter with $663.6 million in cash, cash equivalents, and investments.

In Tuesday morning trading on the New York Stock Exchange, shares of Waters were down 3 percent to $377.05.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.